Mabwell (Shanghai) Bioscience Co., Ltd. (SHA:688062)

Market Cap	9.45B -48.2%
Revenue (ttm)	873.99M +371.4%
Net Income	-939.72M
EPS	-2.31
Shares Out	445.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,450,749
Open	21.59
Previous Close	21.79
Day's Range	21.01 - 22.50
52-Week Range	21.10 - 48.48
Beta	0.52
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2026

About SHA:688062

Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; MAILISHENG, an albipagrastim alfa injection; and JUNMAIKANG, an autoimmune Adalimumab injection. It also provide...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 1,356
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688062

Financial Performance

In 2025, SHA:688062's revenue was 662.52 million, an increase of 231.62% compared to the previous year's 199.78 million. Losses were -969.33 million, -7.14% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 23, 2026

Data Sources Report a data error